Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis.

Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Circulation (2014) 0.98

Vascular permeability in cerebral cavernous malformations. J Cereb Blood Flow Metab (2015) 0.82

Endothelial chromosome 13 deletion in congenital heart disease-associated pulmonary arterial hypertension dysregulates SMAD9 signaling. Am J Respir Crit Care Med (2015) 0.80

Introduction to cerebral cavernous malformation: a brief review. BMB Rep (2016) 0.76

Rho kinase as a target for cerebral vascular disorders. Future Med Chem (2015) 0.76

Genetics of cerebral cavernous malformations: current status and future prospects. J Neurosurg Sci (2015) 0.76

Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14. Front Genet (2015) 0.75

Constitutional de novo and postzygotic mutations in isolated cases of cerebral cavernous malformations. Mol Genet Genomic Med (2016) 0.75

FAM222B Is Not a Likely Novel Candidate Gene for Cerebral Cavernous Malformations. Mol Syndromol (2016) 0.75

Nuclear Localization of Integrin Cytoplasmic Domain-associated Protein-1 (ICAP1) Influences β1 Integrin Activation and Recruits Krev/Interaction Trapped-1 (KRIT1) to the Nucleus. J Biol Chem (2016) 0.75

Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor. Childs Nerv Syst (2017) 0.75

Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05

Quality scores and SNP detection in sequencing-by-synthesis systems. Genome Res (2008) 10.49

Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum Mol Genet (1999) 3.15

The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases. Nat Med (2009) 3.05

Natural history of the cavernous angioma. J Neurosurg (1991) 3.02

An analysis of the natural history of cavernous angiomas. J Neurosurg (1991) 2.97

Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet (1999) 2.79

Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med (1988) 2.65

Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 2.62

Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet (2003) 2.58

CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum Mol Genet (2005) 2.52

Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med (2010) 2.23

[131 cases of cavernous angioma (cavernomas) of the CNS, discovered by retrospective analysis of 24,535 autopsies]. Neurochirurgie (1989) 2.10

A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet (2008) 2.02

Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis. Hum Mol Genet (2008) 1.95

Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke (2011) 1.91

Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 1.88

The myosin phosphatase targeting protein (MYPT) family: a regulated mechanism for achieving substrate specificity of the catalytic subunit of protein phosphatase type 1δ. Arch Biochem Biophys (2011) 1.86

Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke (2005) 1.70

Genotype-phenotype correlations in cerebral cavernous malformations patients. Ann Neurol (2006) 1.55

Rho kinase inhibition rescues the endothelial cell cerebral cavernous malformation phenotype. J Biol Chem (2010) 1.51

A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet (2010) 1.39

Growth, subsequent bleeding, and de novo appearance of cerebral cavernous angiomas. Neurosurgery (1996) 1.32

Cerebral cavernous malformation 2 protein promotes smad ubiquitin regulatory factor 1-mediated RhoA degradation in endothelial cells. J Biol Chem (2009) 1.23

Cerebral cavernous malformations: somatic mutations in vascular endothelial cells. Neurosurgery (2009) 1.10

Factors affecting PCR-mediated recombination. Environ Microbiol (2002) 1.06

Phasic contractions of isolated human myometrium are associated with Rho-kinase (ROCK)-dependent phosphorylation of myosin phosphatase-targeting subunit (MYPT1). Mol Hum Reprod (2011) 0.96

Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet (2013) 0.88

The putative role of the venous system in the genesis of vascular malformations. Neurosurg Focus (2009) 0.82

Extreme de novo appearance of cerebral cavernous malformations: case report. Neurosurgery (2008) 0.78

A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet (2010) 1.39